Management of Metastatic Carcinoma of the Prostate

Overview

1. Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) - also called castration-sensitive
2. Metastatic Castration-Resistant Prostate Cancer (mCRPC) - disease that progresses despite castrate testosterone levels

1. Androgen Deprivation Therapy (ADT) - The Foundation

Methods of Androgen Deprivation

• GnRH agonists cause an initial testosterone "flare" (LH surge) before suppression. Patients with significant metastatic disease must receive a short-course antiandrogen (bicalutamide, flutamide) to block the flare.
• GnRH antagonists (degarelix, oral relugolix) act directly without flare. Relugolix reduces major adverse cardiovascular events (nonfatal MI, stroke, death) by ~50% compared to leuprolide, making it preferred in patients with cardiovascular risk.

2. Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

A. ADT + Docetaxel (Chemohormonal Therapy)

• Extends median OS by ~17 months vs. ADT alone in high-volume disease (defined as: visceral metastasis OR ≥4 bone lesions with ≥1 beyond vertebrae/pelvis)
• PSA ≤ 0.2 ng/mL at 7 months is a favorable prognostic marker for longer OS

B. ADT + Novel Hormonal Agents (NHA)

3. Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Treatment Sequencing Principles

• If progressing on ADT + first-generation antiandrogen: withdraw the antiandrogen first (antiandrogen withdrawal syndrome can temporarily lower PSA)
• If docetaxel was used in mHSPC: retreatment is reasonable if progression was >12 months after last use
• If progression is rapid after docetaxel: switch to cabazitaxel
• If an NHA was used in mHSPC: do NOT use another NHA in mCRPC (cross-resistance); switch to a different mechanism (e.g., docetaxel)

FDA-Approved Agents in mCRPC

4. Molecular/Genomic Testing

• HRR mutations (BRCA1, BRCA2, ATM, CDK12, etc.) - PARP inhibitor eligibility
• MSI-H / dMMR / TMB-high - pembrolizumab eligibility
• Lynch syndrome genes - immunotherapy benefit

5. Bone Health and Supportive Care

• Calcium + Vitamin D supplements
• Bisphosphonates (zoledronic acid) or denosumab (RANK-L inhibitor) for established osteoporosis/bone metastases
• Monitor for: hot flashes, weight gain, anemia (treat with erythropoietin if symptomatic), dyslipidemia, sexual dysfunction, cardiovascular risk

6. Recent Evidence (2024-2026)

• EAU 2024 Guidelines (PMID 38688773) updated management of relapsing and metastatic PCa
• 177Lu-PSMA and 225Ac-PSMA (actinium-225, alpha therapy) emerging as promising agents in mCRPC - recent systematic reviews show response rates and meta-analyses support their efficacy
• Cardiovascular safety of ARSIs: Network meta-analysis (2025, PMID 39237679) documents increased cardiovascular events with androgen receptor signaling inhibitors - reinforcing monitoring and preferring relugolix in high-risk patients

Summary Algorithm

Metastatic PCa
├── mHSPC
│   ├── ADT + Docetaxel (high-volume)
│   ├── ADT + NHA (abiraterone/enzalutamide/apalutamide/darolutamide)
│   └── ADT + Docetaxel + NHA (triplet, de novo high-volume)
│
└── mCRPC (continue ADT lifelong)
    ├── NHA naive → Abiraterone / Enzalutamide / Darolutamide
    ├── Chemotherapy → Docetaxel → Cabazitaxel
    ├── Bone mets (symptomatic, no visceral) → Radium-223
    ├── PSMA+ → 177Lu-PSMA-617
    ├── HRR mutation → Olaparib / Rucaparib
    ├── MSI-H/dMMR/TMB-high → Pembrolizumab
    ├── Asymptomatic/minimal → Sipuleucel-T
    └── Neuroendocrine transformation → Cisplatin/carboplatin + Etoposide

Newer Surgical Treatment Modalities for BPH

1. Laser-Based Therapies

A. Holmium Laser Enucleation of the Prostate (HoLEP) ⭐

• Laser: Ho:YAG (holmium:yttrium-aluminium-garnet) at 2140 nm, pulsed emission
• Mechanism: Strongly absorbed by water; absorption depth of 0.4 mm with excellent hemostasis; coagulates vessels up to 2-3 mm
• Technique: The surgeon follows anatomic planes (using the surgical capsule as a landmark) to enucleate entire prostatic lobes en bloc. Lobes are pushed into the bladder, then morcellated intravesically into small fragments for irrigation
• Advantage over TURP: Size-independent - can treat any prostate size (40-200 g or even larger), historically reserved for glands that would have required open prostatectomy
• Evidence: Multiple meta-analyses confirm equivalence or superiority to TURP in symptom improvement (IPSS), Qmax, and postvoid residual (PVR), with significantly lower blood transfusion risk (no TUR syndrome as normal saline irrigation is used)
• Limitations: Steep learning curve; morcellator-associated bladder injury risk (bladder fibrosis, even cystectomy in catastrophic cases); overnight stay + catheter removal next day
• Predecessor: HoLRP (holmium laser resection of prostate) - lobes resected in large pieces rather than enucleated; now largely replaced by HoLEP

B. Thulium Laser Enucleation of the Prostate (ThuLEP / TmLEP)

• Laser: Thulium:YAG at 2013 nm, continuous-wave emission
• Tissue interaction: Similar to holmium, strongly absorbed by water; however the continuous wave allows smoother tissue vaporization-cutting (vaporsection technique)
• Technique: Anatomic enucleation analogous to HoLEP, with morcellator use - results are essentially equivalent
• A randomized trial (Netsch et al., 2017) comparing ThuLEP (48 pts) vs. HoLEP (46 pts) showed comparable outcomes for both
• Advantages: Potentially smoother resection surface; some surgeons feel it provides better hemostasis than holmium during vaporization
• ThuVARP (Thulium vapor resection): An alternative technique using thulium for vaporization-resection rather than enucleation

C. KTP/GreenLight Photoselective Vaporization of the Prostate (PVP)

• Laser: KTP (potassium titanyl phosphate) or LBO crystal at 532 nm (green wavelength); available as 80-W, 120-W ("HPS"), and 180-W ("XPS") systems
• Mechanism: Selectively absorbed by oxyhemoglobin in vascular prostatic tissue; causes immediate photoselective vaporization with simultaneous coagulation of the underlying tissue
• Irrigation: Normal saline - completely eliminates TUR syndrome (dilutional hyponatremia)
• Key advantage: Can be used safely in patients on anticoagulation or antiplatelet therapy (a major clinical advantage); blood transfusion risk extremely rare (OR 0.10 vs. monopolar TURP)
• Technique: Continuous sweeping motion, serial circumferential vaporization; no tissue available for histology (unlike TURP or HoLEP)
• Complications:
  • Postoperative dysuria and storage symptoms (self-limiting, 0-25% - resolves within 3 months)
  • Capsular perforation: 0.2-1%
  • Epididymitis: 5-7%; UTI: 1-20% (necrotic tissue harbors bacteria)
  • Reoperation for residual adenoma more common than HoLEP
• Limitation: No tissue for histology; early learning curve associated with irregular vaporization depth

2. Thermotherapy-Based Minimally Invasive Therapies

A. Transurethral Microwave Thermotherapy (TUMT)

• Principle: Microwave energy delivered via a urethral antenna raises intraprostatic temperature to 45-80°C, causing coagulation necrosis of prostatic tissue
• High-energy (HE) protocols produce more tissue destruction and better outcomes but more postoperative retention
• Office-based procedure - performed under local anesthesia/sedation
• Advantages vs. TURP: Lower risk of retrograde ejaculation, stricture, hematuria, blood transfusion, and TUR syndrome
• Disadvantages: Inferior long-term durability vs. TURP; higher re-treatment rates; prolonged catheterization post-procedure (due to urinary retention); mechanism of action still debated
• Current role: Appropriate when medical therapy fails, but patient wants to avoid surgical risk; occupies a "lower-efficacy/low-risk" niche

B. Transurethral Needle Ablation (TUNA)

• FDA approved: 1996 (original); significantly updated 2003; first performed 1993
• Mechanism: Radiofrequency (RF) energy delivered via two needles deployed from a urethral catheter directly into prostatic parenchyma at right angles; needles are PTFE-coated near the urethra to protect it from heat
• The needles create focused coagulation necrosis at 100°C within the stroma while sparing the urethra
• Office-based under local anaesthesia
• Advantage: Preserves antegrade ejaculation (lower rate of retrograde ejaculation vs. TURP)
• Limitation: Inferior efficacy and durability compared to TURP; requires retreatment more often

3. Non-Thermal Minimally Invasive Therapies (Office-Based MISTs)

A. Prostatic Urethral Lift (UroLift)

• Concept: Small permanent implants (transprostatic sutures/staples) are deployed via a cystoscope to mechanically retract and compress the lateral lobes of the prostate, opening the prostatic urethra without cutting or heat
• Key advantage: Preservation of ejaculatory function - the only MIST with consistent evidence of preserved antegrade ejaculation
• Ideal for: Men with lateral lobe enlargement, no median lobe; those concerned about sexual function
• Limitation: Not suitable for very large glands or prominent median lobes; efficacy inferior to TURP/HoLEP in objective flow measures; re-treatment rates higher than ablative procedures
• The 2024 systematic review on re-intervention rates confirms higher retreatment rates for UroLift vs. ablative procedures

B. Water Vapor Thermal Therapy (Rezūm)

• Mechanism: Convective thermal energy delivered as water vapor (steam) injected directly into prostatic tissue. The phase change from steam to liquid releases energy (539 cal/g), causing immediate cell death from within the tissue
• A transurethral needle is deployed and steam is injected in brief pulses (9-second bursts) into transition zone tissue
• Advantages: Preservation of ejaculatory function; office-based under local anesthesia/sedation; treats median lobe
• Efficacy: Durable symptom improvement at 4-5 years with low re-treatment rates
• The 2024 systematic review (PMID 38069654) confirms effectiveness of water vapor energy for BPH
• Limitation: Temporary urinary retention post-procedure (catheter required for ~3-5 days); not ideal for very large glands

C. Aquablation (Waterjet Ablation - AQUABEAM)

• Mechanism: A robotically-guided high-velocity waterjet (aquablation) removes prostatic tissue using image-guided robotic arm combined with real-time ultrasound
• The TRUS probe maps the prostate; the surgeon defines the treatment zone; the robotic system delivers the controlled waterjet
• Advantages:
  • Size-independent (can treat large and irregular glands 30-150 mL)
  • Tissue-sparing of the ejaculatory ducts (preserves ejaculation better than TURP)
  • Does not use heat - no thermal damage
  • Can provide histological tissue
• Limitation: Significant bleeding risk (cauterization required after ablation); performed in operating room under general/regional anesthesia; requires TRUS guidance expertise

4. Prostatic Artery Embolization (PAE)

• Category: Interventional radiology (not urologic surgery per se)
• Mechanism: Microspheres are injected via femoral artery catheterization to selectively embolize the prostatic arteries, causing ischemic infarction and volume reduction of the prostate
• No tissue removal - reduction achieved through ischemia/atrophy
• Outcomes: Significant improvement in AUA-SS and Qmax; prostate volume reduction ~27%; inferior to TURP in objective urodynamic improvement
• Advantages: No anesthesia requirement; no retrograde ejaculation; useful in very large glands (>80-100 mL) or those unfit for surgery
• Complications:
  • Post-embolization syndrome: pain, fever (0-22%)
  • Contrast nephropathy (contraindicated in contrast allergy)
  • Radiation exposure
  • Bladder wall ischemia (rare but serious)
  • Technical failure: tortuous vessels, atherosclerosis, aberrant anatomy (prostatic artery arises from 5 different trunks - most commonly internal pudendal artery 34%)
• Two RCTs comparing PAE vs. TURP published to date; TURP outperforms PAE in urodynamic obstruction relief but PAE is less morbid
• Per 2024 meta-analysis: PAE is effective but inferior to surgical options in objective parameters

5. Open Simple Prostatectomy (Millin's / Freyer's) - Modernized

• Robot-assisted simple prostatectomy (RASP): Minimally invasive laparoscopic/robotic enucleation offering shorter hospitalization and reduced blood loss vs. open approach

Summary Comparison Table

AUA Guideline 2023 Framework

• Medical therapy fails
• Symptoms remain bothersome
• Objective indications arise: acute urinary retention, bladder calculi, azotemia, recurrent UTI, recurrent hematuria

Recent Evidence Highlights

• HoLEP vs. TURP: 2023 meta-analysis (PMID 37561537) confirms HoLEP superiority in Qmax improvement and lower retreatment rates
• Ejaculation sparing: 2025 systematic review (PMID 38615071) shows UroLift and Rezūm have the best ejaculatory preservation, with HoLEP having the highest rate of retrograde ejaculation among laser techniques
• Geriatric population: 2024 systematic review (PMID 38656693) found office-based MISTs (UroLift, Rezūm) have favorable safety profiles in elderly/frail patients

Medical Management of Carcinoma of the Prostate

Physiological Basis

1. GnRH (hypothalamus) → stimulates LH/FSH (anterior pituitary)
2. LH → stimulates Leydig cells (testis) → produce testosterone (95% of circulating androgens)
3. Adrenal glands contribute ~5% via DHEA, DHEA-S, androstenedione
4. In prostate cells: testosterone → DHT (by 5α-reductase) → binds androgen receptor (AR) → nuclear translocation → gene transcription → cell proliferation

Classification of Medical Hormonal Agents

LEVEL 1 - Hypothalamic-Pituitary Axis

A. GnRH Agonists (LHRH Agonists)

• Bind GnRH receptor in anterior pituitary
• Initial effect (Days 1-7): Stimulate LH/FSH release → "testosterone flare" (serum testosterone rises transiently)
• Sustained effect (after 14-21 days): Down-regulate GnRH receptors → LH/FSH suppressed → testosterone falls to castrate levels (<50 ng/dL) within 3-4 weeks

• In patients with bone metastases, vertebral lesions, or severe obstructive symptoms, the initial testosterone surge can precipitate:
  • Acute bone pain / fracture
  • Spinal cord compression
  • Urinary retention
  • DIC (rare)
• Prevention: Co-administer an antiandrogen (bicalutamide, flutamide) for 2-4 weeks before and during initial agonist therapy to block flare

B. GnRH Antagonists (LHRH Antagonists)

• No flare - safe in patients with spinal cord compression, DIC, large bone metastases
• Relugolix preferred in patients with cardiovascular risk

C. Estrogens (Historical)

• Diethylstilbestrol (DES): 1-3 mg/day oral; achieves castration by negative feedback on hypothalamic-pituitary axis + possible direct cytotoxic effect
• Largely replaced by GnRH agents due to cardiovascular and thromboembolic toxicity (DVT, PE, MI, stroke)
• Transdermal estradiol avoids hepatic first-pass and may have fewer cardiovascular effects - under active investigation

LEVEL 2 - Adrenal Androgen Synthesis Inhibitors

Abiraterone Acetate

• Mechanism: Irreversible inhibitor of CYP17A1 (17α-hydroxylase/17,20-lyase) - the key enzyme in androgen biosynthesis in adrenal glands, testes, and within the tumor itself
• Blocks conversion of pregnenolone/progesterone to DHEA and androstenedione
• Dose: 1000 mg oral, once daily (on empty stomach) + prednisone 5 mg twice daily (required to prevent mineralocorticoid excess: hypertension, hypokalemia, fluid retention)
• Indications:
  • mHSPC (metastatic hormone-sensitive): ADT + abiraterone (LATITUDE trial, STAMPEDE trial) - improves OS equivalent to docetaxel, with better tolerability
  • mCRPC (before and after chemotherapy)
• Key trials: LATITUDE, STAMPEDE, COU-AA-302, COU-AA-301

Ketoconazole

• Mechanism: Non-selective antifungal that also inhibits CYP17A1 and other P450 enzymes involved in steroidogenesis
• Dose: 400 mg orally three times daily; must add hydrocortisone (to prevent adrenal insufficiency)
• Older agent; significant hepatotoxicity; largely replaced by abiraterone
• Still used for rapid androgen suppression (alongside abiraterone) in emergencies (spinal cord compression, DIC) due to rapid onset

Aminoglutethimide

• Older adrenal androgen synthesis inhibitor; largely obsolete; replaced by ketoconazole and abiraterone

LEVEL 3 - Androgen Receptor (AR) Antagonists

First-Generation Antiandrogens (Non-Steroidal)

1. Combined with GnRH agonist to block testosterone flare at initiation
2. Combined androgen blockade (CAB) = GnRH agonist + antiandrogen (marginal survival benefit over monotherapy in meta-analysis)
3. Monotherapy in selected patients with locally advanced disease

Second-Generation (Novel) AR Antagonists ⭐

Combined Androgen Blockade (CAB)

• Meta-analysis suggests a small but statistically significant survival advantage (~2-3%) over monotherapy
• Must balance against increased side effects and cost
• With modern second-generation agents (enzalutamide, apalutamide, darolutamide), the concept of "combination" is now achieved more effectively in the ADT + NHA paradigm

Chemotherapy

Docetaxel

• Mechanism: Taxane; stabilises microtubules → prevents depolymerisation → mitotic arrest at G2/M phase
• Dose: 75 mg/m² IV every 3 weeks + prednisone; standard 6 cycles in hormone-sensitive setting
• mHSPC (CHAARTED trial): OS advantage of ~14 months (57.6 vs 44 months) in high-volume disease
• mHSPC (STAMPEDE trial): Benefit also shown across disease volume categories
• mCRPC: First-line chemotherapy standard of care (two Phase III trials established this)
• Toxicities: Febrile neutropenia (~6%), peripheral neuropathy, alopecia, fatigue, fluid retention, nail changes

Cabazitaxel

• Second-generation taxane with poor affinity for P-glycoprotein (overcomes taxane resistance)
• Indication: mCRPC after docetaxel failure
• Dose: 20-25 mg/m² every 3 weeks + prednisone
• Prolongs survival vs. mitoxantrone in docetaxel-refractory mCRPC (TROPIC trial)
• Toxicities: More pronounced myelosuppression than docetaxel; neutropenia, diarrhea

Mitoxantrone

• Older anthracenedione; used for palliation (pain relief from bone metastases) in mCRPC; modest anti-tumor effect; not shown to improve survival

PARP Inhibitors (Targeted Therapy for HRR-Mutated mCRPC)

Immunotherapy

Sipuleucel-T (Provenge)

• Type: Autologous cellular immunotherapy (dendritic cell vaccine)
• Patient's own peripheral blood mononuclear cells are extracted, pulsed ex-vivo with PA2024 (prostatic acid phosphatase fused to GM-CSF), then reinfused as activated dendritic cells
• Induces T-cell immune response against prostatic acid phosphatase (PAP), expressed by >95% of prostate cancers
• Indication: Asymptomatic or minimally symptomatic mCRPC (regardless of prior therapy)
• Improves OS by ~4 months vs. placebo (IMPACT trial)
• Toxicities: Infusion-related reactions (chills, fever, fatigue, nausea) - usually transient

Pembrolizumab (PD-1 inhibitor)

• Checkpoint inhibitor; FDA-approved in mCRPC for tumors that are:
  • MSI-H (microsatellite instability-high)
  • dMMR (mismatch repair-deficient)
  • TMB-high (≥10 mutations/megabase)
• These genomic features predict response regardless of tumor type (tissue-agnostic approval)

Bone-Targeting Agents

Radium-223 (Xofigo)

• Alpha-emitting radiopharmaceutical; mimics calcium; selectively incorporates into bone metastases
• Alpha particles cause double-strand DNA breaks in adjacent tumor cells with very short range (2-10 cell diameters) - minimal marrow toxicity compared to beta emitters
• Indication: Symptomatic bone metastases in mCRPC with no known visceral metastases
• Improves OS by ~3.6 months vs. placebo (ALSYMPCA trial)
• 6 monthly injections IV
• Toxicities: Nausea, diarrhea, bone marrow suppression, fracture risk (do NOT combine with abiraterone + prednisone as per updated guidance)

177Lu-PSMA-617 (Lutetium vipivotide tetraxetan / Pluvicto)

• Theranostic agent - targets Prostate-Specific Membrane Antigen (PSMA), highly expressed in prostate cancer
• Requires positive PSMA PET/CT scan as prerequisite
• Beta-emitting lutetium delivers radiation directly to PSMA-expressing tumor cells
• Indication: PSMA-positive mCRPC after prior NHA and docetaxel (VISION trial - OS improvement)
• Actinium-225 PSMA (Ac-225): Alpha-emitting PSMA theranostic - under active investigation; 2025 meta-analysis (PMID 40093902) supports efficacy

Denosumab & Zoledronic Acid (Bone-Protective Agents)

• Denosumab (RANK-L inhibitor): Prevents osteoclast-mediated bone resorption; reduces skeletal-related events (SREs) in mCRPC with bone metastases
• Zoledronic acid (bisphosphonate): IV bisphosphonate; also reduces SREs
• Both are indicated in mCRPC with bone metastases to reduce pathological fractures, spinal cord compression, need for radiotherapy/surgery to bone

Adjuvant/Neoadjuvant Medical Therapy in Non-Metastatic Disease

• Localised intermediate/high-risk disease + radiotherapy: ADT (GnRH agonist) given concurrently with and for 2-3 years after radiation - significantly improves OS and disease control
• Post-prostatectomy with lymph node involvement: Early ADT shows definitive survival advantage (Messing trial)
• Biochemical relapse (PSA rise after definitive therapy): ADT may be initiated, particularly if PSA doubling time is short (<6-12 months), indicating high risk of clinical metastases

Side Effects of ADT and Their Management

Treatment Summary by Stage

Stage/Scenario          Medical Treatment
─────────────────────────────────────────────────────────────────────
Localised, intermediate/ 
high-risk + RT           ADT (GnRH agonist) × 2-3 years
────────────────────────────────────────────────────────────────────
Biochemical PSA relapse  Antiandrogen withdrawal (if on combined)
                         → ADT (GnRH agonist/relugolix)
────────────────────────────────────────────────────────────────────
mHSPC (high-volume)      ADT + Docetaxel (6 cycles)
                         OR ADT + Abiraterone/Enzalutamide/
                            Apalutamide/Darolutamide
                         OR Triplet: ADT + Docetaxel + Abiraterone
────────────────────────────────────────────────────────────────────
mHSPC (low-volume)       ADT + NHA (abiraterone/enzalutamide/
                              apalutamide/darolutamide)
────────────────────────────────────────────────────────────────────
nmCRPC                   ADT + Enzalutamide OR Apalutamide 
                              OR Darolutamide (delay metastases ~2 yrs)
────────────────────────────────────────────────────────────────────
mCRPC (NHA-naive)        Continue ADT + Abiraterone/Enzalutamide/
                              Darolutamide
────────────────────────────────────────────────────────────────────
mCRPC (post-NHA)         Docetaxel → Cabazitaxel
                         Radium-223 (bone mets, no visceral)
                         177Lu-PSMA-617 (PSMA+)
                         Olaparib/Rucaparib (HRR mutations)
                         Pembrolizumab (MSI-H/dMMR/TMB-high)
                         Sipuleucel-T (asymptomatic/minimal)
────────────────────────────────────────────────────────────────────
Neuroendocrine           Carboplatin/cisplatin + Etoposide
transformation
────────────────────────────────────────────────────────────────────